MetaVia Sees Obesity Opportunities Despite Challenging US Market
Novel Non-Titrated Contender
Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.
